The SWIFT-1 and SWIFT-2 trials, published in The New England Journal of Medicine in 2024, investigated the efficacy of depemokimab in patients with severe uncontrolled asthma and an eosinophilic phenotype.
Key Findings:
- Primary Outcome:
- In SWIFT-1, the annualized rate of exacerbations was 0.46 in the depemokimab group versus 1.11 in the placebo group, with a rate ratio of 0.42 (95% CI: 0.30-0.59, P < 0.001).
- In SWIFT-2, the annualized rate of exacerbations was 0.56 in the depemokimab group versus 1.08 in the placebo group, with a rate ratio of 0.52 (95% CI: 0.36-0.73, P < 0.001).
- Secondary Outcome: There was no significant between-group difference in the change from baseline in the SGRQ score in either trial.
Conclusion:
Depemokimab significantly reduced the annualized rate of exacerbations in patients with severe asthma with an eosinophilic phenotype.